{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:51Z","timestamp":1781639691384,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary immune thrombocytopenia (ITP) is generally a self-limiting disorder in children; however, a subset of cases becomes refractory to conventional treatments or progresses to chronic disease. Managing such refractory instances remains a significant clinical challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>We report the case of a 5-year-old child with refractory ITP that was not adequately controlled with standard therapies, including intravenous immunoglobulin, corticosteroids, and rituximab. Following disease recurrence and limited response to these interventions, the novel biologic agent telitacicept was administered. This intervention led to marked clinical improvement. The diagnostic evaluation, therapeutic course, and successful use of telitacicept are comprehensively detailed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case illustrates the potential benefit of telitacicept in the management of pediatric refractory ITP, particularly when conventional treatment options have been exhausted. Further studies are warranted to explore its efficacy and safety in similar challenging cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-026-06641-9","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:14:43Z","timestamp":1772536483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel use of telitacicept in primary immune thrombocytopenia: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Yini","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"2","key":"6641_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","volume":"115","author":"D Provan","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168\u201386.","journal-title":"Blood"},{"issue":"22","key":"6641_CR2","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","volume":"124","author":"G Moulis","year":"2014","unstructured":"Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308\u201315.","journal-title":"Blood"},{"issue":"3","key":"6641_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010;85(3):174\u201380.","journal-title":"Am J Hematol"},{"issue":"5","key":"6641_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1542\/peds.2012-2021","volume":"131","author":"C Kime","year":"2013","unstructured":"Kime C, Klima J, Rose MJ, O\u2019Brien SH. Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children\u2019s hospitals. Pediatrics. 2013;131(5):880\u20135.","journal-title":"Pediatrics"},{"issue":"22","key":"6641_CR5","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","volume":"121","author":"CE Neunert","year":"2013","unstructured":"Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld E, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121(22):4457\u201362.","journal-title":"Blood"},{"issue":"11","key":"6641_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"10","key":"6641_CR7","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2008-03-138487","volume":"112","author":"CE Neunert","year":"2008","unstructured":"Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld EJ, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112(10):4003\u20138.","journal-title":"Blood"},{"issue":"7","key":"6641_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood.2019003599","volume":"135","author":"O Miltiadous","year":"2020","unstructured":"Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472\u201390.","journal-title":"Blood"},{"issue":"4","key":"6641_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"6641_CR10","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, K\u00fchne, T, K DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"Blood Adv"},{"issue":"9","key":"6641_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","volume":"28","author":"X Huang","year":"2024","unstructured":"Huang X, Lin F, Chen H. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clin Exp Nephrol. 2024;28(9):902\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"6641_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10067-025-07348-5","volume":"44","author":"F Fang","year":"2025","unstructured":"Fang F, Duan H, Ding S. Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study. Clin Rheumatol. 2025;44(3):1113\u201322.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"6641_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10238-025-01640-z","volume":"25","author":"T Feng","year":"2025","unstructured":"Feng T, Zhang M, Wang J, Li Y, Cui Y. Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study. Clin Exp Med. 2025;25(1):105.","journal-title":"Clin Exp Med"},{"issue":"1","key":"6641_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.yapd.2024.02.007","volume":"71","author":"M Gotesman","year":"2024","unstructured":"Gotesman M, Shear M, Raheel S, Procassini M, Panosyan EH. Pediatric Immune Thrombocytopenia. Adv Pediatr. 2024;71(1):229\u201340.","journal-title":"Adv Pediatr"},{"issue":"1","key":"6641_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","volume":"16","author":"XG Liu","year":"2023","unstructured":"Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol. 2023;16(1):4.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"6641_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","volume":"16","author":"S Audia","year":"2017","unstructured":"Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620\u201332.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"6641_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1359-6101(01)00025-9","volume":"13","author":"RK Do","year":"2002","unstructured":"Do RK, Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev. 2002;13(1):19\u201325.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"6641_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","volume":"75","author":"LS Evans","year":"2023","unstructured":"Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, et al. Povetacicept, an Enhanced Dual APRIL\/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023;75(7):1187\u2013202.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"6641_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12887-025-05778-3","volume":"25","author":"Y Meng","year":"2025","unstructured":"Meng Y, Ying M, Hongwen Z, Li H, Xiaopeng T. Telitacicept for lupus nephritis with BAFF and APRIL double positivity in children: a case report. BMC Pediatr. 2025;25(1):422.","journal-title":"BMC Pediatr"},{"issue":"1","key":"6641_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12969-025-01159-3","volume":"23","author":"X Ma","year":"2025","unstructured":"Ma X, He Y, Shao P, Guo L, Liang W, Zhou J, et al. Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study. Pediatr Rheumatol Online J. 2025;23(1):104.","journal-title":"Pediatr Rheumatol Online J"},{"key":"6641_CR21","doi-asserted-by":"crossref","unstructured":"Luo C, Su S, Liu J, Lin J, Song J, Chen Z et al. Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting -Adjusted Comparison to a Historical Control Group Treated With Belimumab. Arthritis Rheumatol. 2025.","DOI":"10.1002\/art.43417"},{"issue":"4","key":"6641_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/etm.2024.12660","volume":"28","author":"H Zhu","year":"2024","unstructured":"Zhu H, Hu HQ, Wei HL, Zhang DX, Yang H, Zhang QK, Jin L. Efficacy and safety of telitacicept in patients with lupus nephritis. Exp Ther Med. 2024;28(4):371.","journal-title":"Exp Ther Med"},{"issue":"3","key":"6641_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00467-025-07023-6","volume":"41","author":"Y Jin","year":"2026","unstructured":"Jin Y, Sheng A, Lin Q, Cen K, Zhao M, Feng C, et al. Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study. Pediatr Nephrol. 2026;41(3):723\u201330.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"6641_CR24","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022;31(8):998\u20131006.","journal-title":"Lupus"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-06641-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:17:46Z","timestamp":1781637466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-06641-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6641"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-06641-9","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Children\u2019s Hospital of Zhejiang University, approval number:2025-IRB-0389-P-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}